Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Capital Employed (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Return on Capital Employed for 6 consecutive years, with 0.26% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 2.0% to 0.26% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.26%, a 2.0% increase, with the full-year FY2025 number at 0.27%, up 10.0% from a year prior.
  • Return on Capital Employed was 0.26% for Q4 2025 at Kymera Therapeutics, up from 0.32% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.13% in Q1 2021 to a low of 0.37% in Q3 2023.
  • A 5-year average of 0.27% and a median of 0.29% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: dropped -13bps in 2023, then increased 14bps in 2024.
  • Kymera Therapeutics' Return on Capital Employed stood at 0.17% in 2021, then crashed by -70bps to 0.29% in 2022, then dropped by -18bps to 0.35% in 2023, then rose by 19bps to 0.28% in 2024, then rose by 6bps to 0.26% in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Return on Capital Employed are 0.26% (Q4 2025), 0.32% (Q3 2025), and 0.33% (Q2 2025).